Efficacy and prognosis of PD-1 inhibitors, trastuzumab, and first-line chemotherapy for HER-2-positive advanced gastric cancer in real-world study

被引：0
|
作者：
Liu, B. [1 ]
Tao, Y. [1 ]
Ke, Y. [1 ]
Rao, W. [1 ]
Liu, Q. [1 ]
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S1470 / S1470
页数：1
相关论文
共 50 条
  • [31] First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.
    Wang, Dahai
    Gao, Qin Ai
    Sun, Yuping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
    Li, Li-Hua
    Chen, Wen-Chao
    Wu, Gang
    DISEASE MARKERS, 2022, 2022
  • [33] A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.
    Gong, Jifang
    Liu, Tianshu
    Fan, Qingxia
    Bai, Li
    Bi, Feng
    Qin, Shukui
    Wang, Jinwan
    Xu, Nong
    Cheng, Ying
    Bai, Yuxian
    Liu, Wei
    Wang, Liwei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] FIRST-LINE TREATMENT IN HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER
    Yamaguchi, K.
    Ooki, A.
    Yamada, T.
    Hara, H.
    Asayama, M.
    Tada, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [35] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Fernando Rivera
    C. Romero
    P. Jimenez-Fonseca
    M. Izquierdo-Manuel
    A. Salud
    E. Martínez
    M. Jorge
    V. Arrazubi
    J. C. Méndez
    P. García-Alfonso
    M. Reboredo
    J. Barriuso
    N. Muñoz-Unceta
    R. Jimeno
    C. López
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1175 - 1181
  • [36] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Rivera, Fernando
    Romero, C.
    Jimenez-Fonseca, P.
    Izquierdo-Manuel, M.
    Salud, A.
    Martinez, E.
    Jorge, M.
    Arrazubi, V.
    Mendez, J. C.
    Garcia-Alfonso, P.
    Reboredo, M.
    Barriuso, J.
    Munoz-Unceta, N.
    Jimeno, R.
    Lopez, C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1175 - 1181
  • [37] Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.
    Chen, Kehe
    Huang, Xianshi
    Yu, Lei
    Lu, Jianxun
    Huang, Fei
    Wang, Zhiguang
    Wei, Yan
    Hou, Encun
    Luo, Min
    Huang, Shiqing
    Hu, Hongbo
    Ou, Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 583 - 583
  • [38] Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Cristina Grávalos
    Carlos Gómez-Martín
    Fernando Rivera
    Inmaculada Alés
    Bernardo Queralt
    Antonia Márquez
    Ulpiano Jiménez
    Vicente Alonso
    Rocío García-Carbonero
    Javier Sastre
    Ramon Colomer
    Hernán Cortés-Funes
    Antonio Jimeno
    Clinical and Translational Oncology, 2011, 13
  • [39] Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Gravalos, Cristina
    Gomez-Martin, Carlos
    Rivera, Fernando
    Ales, Inmaculada
    Queralt, Bernardo
    Marquez, Antonia
    Jimenez, Ulpiano
    Alonso, Vicente
    Garcia-Carbonero, Rocio
    Sastre, Javier
    Colomer, Ramon
    Cortes-Funes, Hernan
    Jimeno, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (03): : 179 - 184
  • [40] Efficacy of PD-1 inhibitors in first-line treatment for advanced gastroesophageal junction and gastric cancer by subgroups: A systematic review and meta-analysis
    Fei, Shengqi
    Lu, Yu
    Chen, Jing
    Qi, Jia
    Wu, Wenxuan
    Wang, Beidi
    Han, Yaxuan
    Wang, Kefan
    Han, Xiaying
    Zhou, Haiyan
    Wang, Jun
    Chen, Jian
    CHEMOTHERAPY, 2023, 68 (04) : 197 - 209
12345